GLP-1 receptor agonists show promise beyond obesity but require careful use due to sarcopenia risk and complex effects on mental health.

As we age and experience less daily physical movement, it is expected that our strength and muscle mass declines slightly as well. However, when gradual muscle loss starts to severely affect an older ...

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / June 19, 2023 / Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), («Biophytis» or the «company»), a clinical-stage biotechnology company ...

Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma. This is an ASCO ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...

Biologic profile to predict overall survival in non-metastatic breast cancer: A latent class analysis on aging biomarkers. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

Sarcopenia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sarcopenia market. A detailed picture ...

Sarcopenia increases the risk for chronic kidney disease and synergistically increases the risk of death. Sarcopenia is associated with an increased risk for chronic kidney disease (CKD) among older ...

According to the latest market report published by the company titled ‘Sarcopenia Treatment Market: Global Industry Analysis 2013 – 2017 and Forecast, 2018 – 2026,’ the global sarcopenia treatment ...

Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress 19-Jun-2023 / 07:00 CET/CEST Biophytis reports clinical results for Sarconeos ...